IL166166A0 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders - Google Patents

Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Info

Publication number
IL166166A0
IL166166A0 IL16616605A IL16616605A IL166166A0 IL 166166 A0 IL166166 A0 IL 166166A0 IL 16616605 A IL16616605 A IL 16616605A IL 16616605 A IL16616605 A IL 16616605A IL 166166 A0 IL166166 A0 IL 166166A0
Authority
IL
Israel
Prior art keywords
quinidine
pharmaceutical compositions
dextromethorphan
neurological disorders
treatment
Prior art date
Application number
IL16616605A
Other languages
English (en)
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30116047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL166166(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of IL166166A0 publication Critical patent/IL166166A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL16616605A 2002-07-17 2005-01-05 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders IL166166A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39666102P 2002-07-17 2002-07-17
PCT/US2003/022303 WO2004006930A1 (fr) 2002-07-17 2003-07-17 Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques

Publications (1)

Publication Number Publication Date
IL166166A0 true IL166166A0 (en) 2006-01-15

Family

ID=30116047

Family Applications (7)

Application Number Title Priority Date Filing Date
IL16616605A IL166166A0 (en) 2002-07-17 2005-01-05 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
IL211593A IL211593A0 (en) 2002-07-17 2011-03-06 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
IL225192A IL225192A (en) 2002-07-17 2013-03-13 Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
IL225190A IL225190A (en) 2002-07-17 2013-03-13 A combination of dextromethorphan and quinidine for the preparation of preparations for the treatment of pseudo-bulbary emotion or emotional laxity
IL225191A IL225191A (en) 2002-07-17 2013-03-13 A combination of dextromethorphan and quinidine for the preparation of preparations for the treatment of neurodegeneration
IL256054A IL256054A (en) 2002-07-17 2017-12-03 A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
IL267381A IL267381A (en) 2002-07-17 2019-06-16 A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL211593A IL211593A0 (en) 2002-07-17 2011-03-06 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
IL225192A IL225192A (en) 2002-07-17 2013-03-13 Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
IL225190A IL225190A (en) 2002-07-17 2013-03-13 A combination of dextromethorphan and quinidine for the preparation of preparations for the treatment of pseudo-bulbary emotion or emotional laxity
IL225191A IL225191A (en) 2002-07-17 2013-03-13 A combination of dextromethorphan and quinidine for the preparation of preparations for the treatment of neurodegeneration
IL256054A IL256054A (en) 2002-07-17 2017-12-03 A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
IL267381A IL267381A (en) 2002-07-17 2019-06-16 A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders

Country Status (24)

Country Link
US (12) US7659282B2 (fr)
EP (6) EP3824889A1 (fr)
JP (12) JP5082032B2 (fr)
KR (7) KR20160055963A (fr)
AT (1) ATE399553T1 (fr)
AU (3) AU2003251971B9 (fr)
BE (1) BE2013C064I2 (fr)
CA (1) CA2492081C (fr)
CY (2) CY1110405T1 (fr)
DE (1) DE60321929D1 (fr)
DK (2) DK1539166T3 (fr)
ES (2) ES2553654T3 (fr)
FR (1) FR13C0062I2 (fr)
HK (2) HK1076052A1 (fr)
HU (2) HUE028100T2 (fr)
IL (7) IL166166A0 (fr)
LU (1) LU92323I2 (fr)
NO (2) NO330626B1 (fr)
PL (2) PL398445A1 (fr)
PT (2) PT1539166E (fr)
RU (1) RU2341265C2 (fr)
SI (2) SI1539166T1 (fr)
TW (1) TWI326214B (fr)
WO (1) WO2004006930A1 (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
AU2003291302A1 (en) * 2002-11-06 2004-06-03 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
WO2006038070A2 (fr) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions et methodes de modulation des canaux ioniques commandes par porte
US20070191411A1 (en) * 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2641392A1 (fr) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Compositions pharmaceutiques comprenant du dextromethorphane et de la quinidine pour le traitement de la depression, de l'anxiete et des troubles neurodegeneratifs
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
EP3825306B8 (fr) 2007-05-01 2023-08-02 Sun Pharmaceutical Industries, Inc. Composés de morphinane
EP3632916B1 (fr) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Composés de morphinane
PL2345653T3 (pl) * 2007-05-01 2013-05-31 Concert Pharmaceuticals Inc Związki morfianu
WO2009006194A1 (fr) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Compositions pharmaceutiques pour le traitement d'un trouble de l'expression émotionnelle involontaire
SI2334678T1 (sl) 2008-09-19 2013-05-31 Concert Pharmaceuticals Inc. Spojine morfinana
US20120122848A1 (en) * 2009-07-29 2012-05-17 Green Cross Corporation (+)-3-hydroxymorphinan derivatives as neuroprotectants
US20110212987A1 (en) * 2009-08-28 2011-09-01 Avanir Pharmaceuticals, Inc. Method of reducing cns and gastrointestinal side affects associated with long-term dextromethorphan/low-dose quinidine combination therapy
US20130053411A1 (en) * 2010-05-03 2013-02-28 Tsh Biopharm Corporation Ltd. Pharmaceutical composition and method for treating hypertension
WO2012123449A1 (fr) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-pipéridinylbenzamides en tant que modulateurs de gpr119
US8569328B1 (en) * 2011-05-24 2013-10-29 Antecip Bioventures Ii Llc Compositions and methods comprising tilidine or related compounds and dextromethorphan
EP2718288B1 (fr) 2011-06-09 2015-03-11 Boehringer Ingelheim International GmbH Pipéridines substituées à titre de modulateurs de gpr119 pour le traitement des troubles métaboliques
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
CN103073496B (zh) * 2013-02-18 2015-08-26 苏州立新制药有限公司 右美沙芬的制备方法
US10716784B2 (en) * 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10780064B2 (en) 2019-01-07 2020-09-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
CA2929415C (fr) * 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Compositions et procedes comprenant du bupropion ou des composes apparentes et du dextromethorphane
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20160324807A1 (en) * 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
RU2020116666A (ru) * 2014-09-14 2020-07-31 Аванир Фармасьютикалз, Инк. Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
WO2016109679A1 (fr) * 2014-12-31 2016-07-07 Markovitz M D Ph D Paul Méthode de traitement de la schizophrénie
WO2017020016A1 (fr) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Composés de morphinane pour le traitement de l'agitation
WO2017117347A1 (fr) * 2015-12-30 2017-07-06 Markovitz M D Paul Méthode de traitement de la schizophrénie
JP7061079B2 (ja) 2016-07-04 2022-04-27 アヴェニール ファーマシューティカルズ， インコーポレイテッド 重水素化デキストロメトルファンの合成方法
WO2018031216A1 (fr) * 2016-08-12 2018-02-15 Steven Rothman Traitement de troubles de l'excitation sexuelle grâce à l'application locale d'agents qui augmentent l'excitabilité membranaire
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
EP3512600A4 (fr) 2016-09-13 2020-05-27 Mindlab LLC Combinaisons de médicaments et traitement du syndrome des jambes sans repos
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CA3062452C (fr) 2017-05-04 2023-10-24 Exciva GmbH Compositions, combinaisons et methodes connexes pour le traitement de troubles neurologiques
TWI795446B (zh) 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN114469882B (zh) * 2022-04-06 2023-10-20 北京剂泰医药科技有限公司 一种右美沙芬奎尼丁口崩片及其应用
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US5034400A (en) 1989-10-20 1991-07-23 Olney John W Method for preventing neurotoxic side effects of NMDA antagonists
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
AU8071894A (en) 1994-09-22 1996-04-09 Jonathan M Licht Compositions useful for the preparation of medicines for treating a variety of intractable disorders
CN1166172A (zh) * 1995-08-03 1997-11-26 达德化学系统公司 奎尼定缀合物及其在免疫测定中的应用
WO2000017366A2 (fr) 1998-09-21 2000-03-30 Transgene S.A. Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament
TR200102876T2 (tr) * 1999-04-07 2006-12-21 Pfizer Products Inc. Bileşim tedavilerinde CYP2D6 önleyicilerinin kullanılması.
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA2641392A1 (fr) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Compositions pharmaceutiques comprenant du dextromethorphane et de la quinidine pour le traitement de la depression, de l'anxiete et des troubles neurodegeneratifs
KR101590378B1 (ko) * 2009-09-07 2016-02-02 에스케이텔레콤 주식회사 근거리 영역 내의 방송통신 융합 구간에 대한 신호 간섭 최소화 시스템 및 방법, 그리고 이에 적용되는 장치

Also Published As

Publication number Publication date
IL267381A (en) 2019-08-29
US20140288114A1 (en) 2014-09-25
JP2020063248A (ja) 2020-04-23
IL225192A (en) 2017-12-31
AU2003251971B2 (en) 2008-02-21
JP2014129384A (ja) 2014-07-10
EP1539166B1 (fr) 2008-07-02
JP6332651B2 (ja) 2018-05-30
EP1980252A3 (fr) 2008-12-24
NO20050807L (no) 2005-02-15
CA2492081C (fr) 2010-09-07
JP2018150368A (ja) 2018-09-27
EP1980252A2 (fr) 2008-10-15
HK1123741A1 (en) 2009-06-26
PT1980252E (pt) 2015-12-01
PL374026A1 (en) 2005-09-19
KR20160055963A (ko) 2016-05-18
HUE028100T2 (en) 2016-11-28
IL225191A (en) 2017-03-30
EP3824889A1 (fr) 2021-05-26
CY2013041I2 (el) 2015-12-09
TWI326214B (en) 2010-06-21
RU2341265C2 (ru) 2008-12-20
KR20120089706A (ko) 2012-08-13
US20180098984A1 (en) 2018-04-12
US20130072517A1 (en) 2013-03-21
JP2011225601A (ja) 2011-11-10
US20120165363A1 (en) 2012-06-28
TW200403997A (en) 2004-03-16
LU92323I2 (fr) 2015-09-22
PL398445A1 (pl) 2012-06-04
JP6097859B2 (ja) 2017-03-15
AU2003251971B9 (en) 2008-04-24
JP2016106150A (ja) 2016-06-16
IL211593A0 (en) 2011-05-31
AU2010212348A1 (en) 2010-09-09
ATE399553T1 (de) 2008-07-15
JP5082032B2 (ja) 2012-11-28
DK1980252T3 (en) 2015-11-30
US20090082384A1 (en) 2009-03-26
US20200276185A1 (en) 2020-09-03
JP2014058575A (ja) 2014-04-03
KR20110010669A (ko) 2011-02-01
ES2309351T3 (es) 2008-12-16
CY1110405T1 (el) 2012-05-23
US20050203125A1 (en) 2005-09-15
KR20130043217A (ko) 2013-04-29
US20190201391A1 (en) 2019-07-04
US20160287576A1 (en) 2016-10-06
SI1980252T1 (sl) 2016-01-29
JP2017036337A (ja) 2017-02-16
JP2016011304A (ja) 2016-01-21
US8227484B2 (en) 2012-07-24
NO330626B1 (no) 2011-05-30
AU2010212348B2 (en) 2013-05-09
KR20050043893A (ko) 2005-05-11
AU2003251971A1 (en) 2004-02-02
EP3281630A1 (fr) 2018-02-14
BE2013C064I2 (fr) 2022-08-09
SI1539166T1 (sl) 2008-12-31
KR20190143466A (ko) 2019-12-30
WO2004006930A1 (fr) 2004-01-22
EP2322179A1 (fr) 2011-05-18
JP6074000B2 (ja) 2017-02-01
AU2008201775B2 (en) 2010-05-20
HUS1300069I1 (hu) 2016-10-28
IL225191A0 (en) 2013-06-27
KR20130041296A (ko) 2013-04-24
PL213552B1 (pl) 2013-03-29
IL256054A (en) 2018-01-31
NO2013017I2 (no) 2015-09-07
US20140045880A1 (en) 2014-02-13
PT1539166E (pt) 2008-10-14
KR101622446B1 (ko) 2016-05-18
DK1539166T3 (da) 2008-10-20
KR101588095B1 (ko) 2016-01-25
DE60321929D1 (de) 2008-08-14
CA2492081A1 (fr) 2004-01-22
JP2005537268A (ja) 2005-12-08
JP2017088620A (ja) 2017-05-25
JP2021098743A (ja) 2021-07-01
IL225190A (en) 2017-03-30
EP1539166A1 (fr) 2005-06-15
ES2553654T3 (es) 2015-12-10
NO2013017I1 (no) 2014-06-02
US20100137352A1 (en) 2010-06-03
US7659282B2 (en) 2010-02-09
RU2005104418A (ru) 2005-10-27
FR13C0062I2 (fr) 2015-11-20
EP1980252B1 (fr) 2015-08-19
AU2008201775A1 (en) 2008-05-15
EP3459547A1 (fr) 2019-03-27
US20150209347A1 (en) 2015-07-30
CY2013041I1 (el) 2015-12-09
JP2012116858A (ja) 2012-06-21
FR13C0062I1 (fr) 2014-01-03
HK1076052A1 (en) 2006-01-06

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2003094836A3 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ZA201207075B (en) Inhibitors of bruton's tyrosine kinase
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
WO2003068171A3 (fr) Procede et composition pour le traitement d'une inflammation et de troubles neurologiques associes au sida
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1503748A4 (fr) Medicaments servant a attenuer la neurotoxicite induite par le taxane
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
EP1374873B8 (fr) Utilisation de la n-acetyl-d-glucosamine dans la preparation de compositions pharmaceutiques utilisees dans la suppression des effets secondaires causes par la radiotherapie et la chimiotherapie
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
EP1878728A3 (fr) Dérivés de pipérazine et ses homologues supérieurs pour le taritement des maladies associées à l'inflammation